Real-life experience of a lidocaine/tetracaine self-occluding topical anesthetic for dermatological procedures.
Pliaglis
dermatological procedures
lidocaine
self-occluding
tetracaine
topical anesthetic
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
15
05
2021
accepted:
18
10
2021
pubmed:
13
11
2021
medline:
20
7
2022
entrez:
12
11
2021
Statut:
ppublish
Résumé
Pliaglis To evaluate the effectiveness and safety of Pliaglis This retrospective, multicenter study included 35 patients treated with Pliaglis The median and mean pain VAS reported by patients was 2 (range 0-9) and 2.9 (±2.3), respectively. More than 65% of the patients had a VAS score ≤3. The effectiveness reported by investigators was "very good" (median 8 [range 2-10], mean 7.5 [±1.9]), which was strongly correlated with the pain VAS reported by patients (Spearman coefficient = - 0.9; p < 0.001). Forty-five percent of patients reported AEs and they were transient and mostly mild, with a mean intensity score of 1.5 (range 1-3). Tolerability of Pliaglis Pliaglis
Sections du résumé
BACKGROUND
BACKGROUND
Pliaglis
AIMS
OBJECTIVE
To evaluate the effectiveness and safety of Pliaglis
METHODS
METHODS
This retrospective, multicenter study included 35 patients treated with Pliaglis
RESULTS
RESULTS
The median and mean pain VAS reported by patients was 2 (range 0-9) and 2.9 (±2.3), respectively. More than 65% of the patients had a VAS score ≤3. The effectiveness reported by investigators was "very good" (median 8 [range 2-10], mean 7.5 [±1.9]), which was strongly correlated with the pain VAS reported by patients (Spearman coefficient = - 0.9; p < 0.001). Forty-five percent of patients reported AEs and they were transient and mostly mild, with a mean intensity score of 1.5 (range 1-3). Tolerability of Pliaglis
CONCLUSIONS
CONCLUSIONS
Pliaglis
Substances chimiques
Anesthetics, Local
0
Tetracaine
0619F35CGV
Lidocaine
98PI200987
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2939-2944Subventions
Organisme : Cantabria Labs
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Ji M, Liu G, Cui Y, Zhao P. Safety and efficacy concerns of modern strategies of local anesthetics delivery. 3. Biotech. 2020;10(8):333.
Alster T. Review of lidocaine/tetracaine cream as a topical anesthetic for dermatologic laser procedures. Pain Ther. 2013;2(1):11-19.
Pliaglis® [package insert].Industrial Farmacéutica Cantabria; 2017.
Cohen JL. Pain management with a topical lidocaine and tetracaine 7%/7% cream with laser dermatologic procedures. J Drugs Dermatol. 2013;12(9):986-989.
Doshi SN, Friedman PM, Marquez DK, Goldberg LH. Thirty-minute application of the S-Caine peel prior to nonablative laser treatment. Dermatol Surg. 2003;29(10):1008-1011.
Alster TS, Lupton JR. Evaluation of a novel topical anesthetic agent for cutaneous laser resurfacing: a randomized comparison study. Dermatol Surg. 2002;28(11):1004-1006.
Chen JZ, Alexiades-Armenakas MR, Bernstein LJ, Jacobson LG, Friedman PM, Geronemus RG. Two randomized, double-blind, placebo-controlled stud- ies evaluating the S-Caine Peel for induction of local anesthesia before long- pulsed Nd:YAG laser therapy for leg veins. Dermatol Surg. 2003;29(10):1012-1018.
Jih MH, Friedman PM, Sadick N, Marquez DK, Kimyai-Asadi A, Goldberg LH. 60-minute application of S-Caine Peel prior to 1,064 nm long-pulsed Nd:YAG laser treatment of leg veins. Lasers Surg Med. 2004;34(5):446-450.
Alster T, Garden J, Fitzpatrick R, Rendon M, Sarkany M, Adelglass J. Lido- caine/tetracaine peel in topical anesthesia prior to laser-assisted hair removal: Phase-II and Phase-III study results. J Dermatolog Treat. 2014;25(2):174-177.
Chen JZ, Jacobson LG, Bakus AD, et al. Evaluation of the S-Caine Peel for induction of local anesthesia for laser-assisted tattoo removal: random- ized, double-blind, placebo-controlled, multicenter study. Dermatol Surg. 2005;31(3):281-286.
Gahalaut P, Mishra N, Chauhan S, Rastogi MK. Comparison of topical an- esthetics for radiofrequency ablation of achrocordons: eutectic mixture of lignocaine/prilocaine versus lidocaine/tetracaine. ISRN Dermatol. 2014;2014:743027.
Cohen JL, Gold MH. Evaluation of the efficacy and safety of a lidocaine and tetracaine (7/7%) cream for induction of local dermal anesthesia for facial soft tissue augmentation with hyaluronic Acid. J Clin Aesthet Dermatol. 2014;7(10):32-37.
Jain R, Arias GM, Naranjo P, et al. The use of a self-occluding topical anasthetic in daily practice: a non-interventional study. J Drugs Dermatol. 2018;17(4):413-418.
Brumana MB, Milani M, Puviani M. Efficacy of lidocaine 7 %, tetracaine 7 % self-occlusive cream in reducing MAL-cPDT-associated pain in subjects with actinic keratosis: a randomized, single-blind, vehicle-controlled trial (The "3P-Trial"). Photodiagnosis Photodyn Ther. 2020;30:101758.
Caprari E, Viciguerra MT, Milani M. Assessment of clinical efficacy of lidocaine/tetracaine 7%/7% peel cream in fractional microablative laser procedure-associated pain for facial skin aging treatment. A randomized, controlled, single-blind trial. J Cosmet Dermatol. 2021;1-5. https://doi.org/10.1111/jocd.14296. [In Press].
Pliaglis® [package insert]. Galderma Laboratories, L.P.; 2013.
Kennish L, Reidenberg B. A review of the effect of occlusive dressings on lamellar bodies in the stratum corneum and relevance to transdermal absorption. Dermatol Online J. 2005;11(3):7.